title: Finasteride is effective for the treatment of central serous chorioretinopathy.
abstract: PurposeTo evaluate the safety and efficacy of finasteride treatment in patients with central serous chorioretinopathy (CSC).MethodsRetrospective review of 29 eyes of 23 patients who were treated with finasteride for CSC. Previous medical and ocular history, steroid use, length of finasteride treatment, additional treatments for CSC, visual acuity (VA), central macular thickness (CMT), and presence of subretinal fluid (SRF) throughout the follow-up period, and the occurrence of any complications were recorded.ResultsInitial VA was 0.29±0.31 logMAR, and a trend towards improved VA was noted after 3 months (0.25±0.36 logMAR; P=0.07). VA was significantly improved at the final follow-up (0.23±0.27 logMAR; P=0.024). Initial CMT was 354±160 μm, and was significantly reduced after 1 month of treatment (284±77 μm; P=0.002) and this was maintained to the end of follow-up (247±85 μm; P=0.001). A significant reduction in SRF presence was found at all time points, with an overall 75.9% rate of complete resolution. Following discontinuation, SRF recurrence was noted in 37.5% of cases. No adverse events were recorded.ConclusionsFinasteride is a safe and effective treatment for CSC. It may be a possible new option for the initial management of patient with CSC, and a suggested treatment approach is presented.
authors.affiliation: Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA.
authors.forename: E
authors.initials: E
authors.lastname: Moisseiev
authors.affiliation: Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Holmes
authors.affiliation: Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Moshiri
authors.affiliation: Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA.
authors.forename: L S
authors.initials: LS
authors.lastname: Morse
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D018120:Finasteride / Q000627:therapeutic use*; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D058891:5-alpha Reductase Inhibitors; D018120:Finasteride